Alan D. Borthwick
Drug Design & Medicinal Chemistry Consultant
DrugMoldesign
15 Temple Grove
London NW11 7UA
Name/email consistency: high
- Oral oxytocin antagonists. Borthwick, A.D. J. Med. Chem. (2010)
- Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs. Kleanthous, S., Borthwick, A.D., Brown, D., Burns-Kurtis, C.L., Campbell, M., Chaudry, L., Chan, C., Clarte, M.O., Convery, M.A., Harling, J.D., Hortense, E., Irving, W.R., Irvine, S., Pateman, A.J., Patikis, A.N., Pinto, I.L., Pollard, D.R., Roethka, T.J., Senger, S., Shah, G.P., Stelman, G.J., Toomey, J.R., Watson, N.S., West, R.I., Whittaker, C., Zhou, P., Young, R.J. Bioorg. Med. Chem. Lett. (2010)
- The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. Borthwick, A.D., Liddle, J. Med. Res. Rev. (2009)
- The discovery of GSK221149A: a potent and selective oxytocin antagonist. Liddle, J., Allen, M.J., Borthwick, A.D., Brooks, D.P., Davies, D.E., Edwards, R.M., Exall, A.M., Hamlett, C., Irving, W.R., Mason, A.M., McCafferty, G.P., Nerozzi, F., Peace, S., Philp, J., Pollard, D., Pullen, M.A., Shabbir, S.S., Sollis, S.L., Westfall, T.D., Woollard, P.M., Wu, C., Hickey, D.M. Bioorg. Med. Chem. Lett. (2008)
- Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs. Young, R.J., Borthwick, A.D., Brown, D., Burns-Kurtis, C.L., Campbell, M., Chan, C., Charbaut, M., Convery, M.A., Diallo, H., Hortense, E., Irving, W.R., Kelly, H.A., King, N.P., Kleanthous, S., Mason, A.M., Pateman, A.J., Patikis, A.N., Pinto, I.L., Pollard, D.R., Senger, S., Shah, G.P., Toomey, J.R., Watson, N.S., Weston, H.E., Zhou, P. Bioorg. Med. Chem. Lett. (2008)
- Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs. Young, R.J., Borthwick, A.D., Brown, D., Burns-Kurtis, C.L., Campbell, M., Chan, C., Charbaut, M., Chung, C.W., Convery, M.A., Kelly, H.A., Paul King, N., Kleanthous, S., Mason, A.M., Pateman, A.J., Patikis, A.N., Pinto, I.L., Pollard, D.R., Senger, S., Shah, G.P., Toomey, J.R., Watson, N.S., Weston, H.E. Bioorg. Med. Chem. Lett. (2008)
- Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides. Chan, C., Borthwick, A.D., Brown, D., Burns-Kurtis, C.L., Campbell, M., Chaudry, L., Chung, C.W., Convery, M.A., Hamblin, J.N., Johnstone, L., Kelly, H.A., Kleanthous, S., Patikis, A., Patel, C., Pateman, A.J., Senger, S., Shah, G.P., Toomey, J.R., Watson, N.S., Weston, H.E., Whitworth, C., Young, R.J., Zhou, P. J. Med. Chem. (2007)
- 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency. Borthwick, A.D., Davies, D.E., Exall, A.M., Hatley, R.J., Hughes, J.A., Irving, W.R., Livermore, D.G., Sollis, S.L., Nerozzi, F., Valko, K.L., Allen, M.J., Perren, M., Shabbir, S.S., Woollard, P.M., Price, M.A. J. Med. Chem. (2006)
- Design of translactam HCMV protease inhibitors as potent antivirals. Borthwick, A.D. Med. Res. Rev (2005)
- 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. Borthwick, A.D., Davies, D.E., Exall, A.M., Livermore, D.G., Sollis, S.L., Nerozzi, F., Allen, M.J., Perren, M., Shabbir, S.S., Woollard, P.M., Wyatt, P.G. J. Med. Chem. (2005)
- Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability. Borthwick, A.D., Davies, D.E., Ertl, P.F., Exall, A.M., Haley, T.M., Hart, G.J., Jackson, D.L., Parry, N.R., Patikis, A., Trivedi, N., Weingarten, G.G., Woolven, J.M. J. Med. Chem. (2003)
